Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov-Dec;69(6):707-713.
doi: 10.1016/j.ihj.2017.05.024. Epub 2017 Jun 3.

Incidence of drug-induced torsades de pointes with intravenous amiodarone

Affiliations

Incidence of drug-induced torsades de pointes with intravenous amiodarone

Jayaprakash Shenthar et al. Indian Heart J. 2017 Nov-Dec.

Abstract

Aim: To define the incidence, presentation, and outcomes of drug-induced Torsades de Pointes (TdP) with intravenous (IV) amiodarone.

Methods: From January 2014 to August 2016 a total of 268 patients received IV amiodarone, 142 for ventricular tachycardia, 104 for atrial flutter/fibrillation, and 22 for incessant atrial tachycardia. A uniform dosing of amiodarone to yield 1gm/day was used in all patients.

Results: Four of the 268 patients (M:F 1:3) with mean age of 51.25+9.17years developed pause dependent TdP degenerating to VF, after a mean dose of 690+176.63mg, infused over 12+5.88h. The QTc that was 505+9.02ms at the time of TdP normalized to 433.75+6.13ms 48-72h after stopping amiodarone. There was no immediate or late mortality, and patients are well at 5-10 months of follow-up. None of the patients tested positive for LQTS genes.

Conclusion: The incidence of drug-induced TdP with IV amiodarone is about 1.5%. Risk factors include female sex, left ventricular dysfunction, electrolyte abnormalities, baseline prolonged QTc, concomitant beta-blocker, and digoxin therapy. Amiodarone induced TdP has favorable prognosis if recognized and treated promptly, and these patients should not receive amiodarone by any route in future.

Keywords: Acquired LQT; Amiodarone; Proarrhythmia; Torsades de pointes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(a) ECG of case 1 showing atrial flutter with a ventricular rate of 150 beats per minute. (b) ECG of case 1 after defibrillation of TdP six hours after IV amiodarone infusion. The sinus rhythm ECG shows marked sinus bradycardia with prolonged QT interval with QTc interval of 500 ms and R on T ectopic’s.
Fig. 2
Fig. 2
ECG of case 3 showing rapid monomorphic ventricular tachycardia/flutter with LBBB morphology and a ventricular rate of 300 bpm following IV isoprenaline infusion to prevent pause dependent TdP.
Fig. 3
Fig. 3
(a) ECG of case 4 showing sinus bradycardia with QTc of 506 ms after 12 h of IV amiodarone therapy and conversion of atrial fibrillation to sinus rhythm. (b) Continuous monitoring strip of the ECG of case 4 showing pause dependent Torsades de pointes immediately after conversion to sinus rhythm preceded by long-short sequence. The TdP degenerated to ventricular fibrillation requiring DC cardioversion.

Similar articles

Cited by

References

    1. Connolly S.J. Evidence based analysis of amiodarone efficacy and safety. Circulation. 1999;100:2025–2034. - PubMed
    1. Scheinman M.M., Levine J.H., Cannom D.S. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. Circulation. 1995;92(December (11)):3264–3272. - PubMed
    1. Clemo H.F., Wood M.A., Gilligan D.M., Ellenbogen K.A. Intravenous amiodarone for acute heart with atrial tachyarrhythmias. Am J Cardiol. 1998;81(97):594–598. - PubMed
    1. Kirchhof P., Benussi S., Kotecha D. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(October (38)):2893–2962. - PubMed
    1. Molokhia M., Pathak A., Lapeyre-Mestre M., Caturla L., Montastruc J.L., McKeigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in Southwest France. Br J Clin Pharmacol. 2008;66(September (3)):386–395. - PMC - PubMed

LinkOut - more resources